Select ongoing clinical trials with novel combinations
| Agent . | Combination . | Phase . | Line of therapy . | Identifier . |
|---|---|---|---|---|
| Polatuzumab | Rituximab and lenalidomide | 1 | Relapsed | NCT02600897 |
| Polatuzumab | Obinutuzumab, rituximab, venetoclax | 1 | Relapsed | NCT02611323 |
| Polatuzumab | R-EPOCH | 1 | Frontline | NCT04231877 |
| Polatuzumab | ± RGemOx | 3 | Relapsed | NCT04182204 |
| Polatuzumab | + R-CHOP vs + R-CHP | 3 | Frontline | NCT04332822 |
| Venetoclax | Obinutuzumab, lenalidomide, ibrutinib, prednisone | 1 | Relapsed | NCT03223610 |
| Venetoclax | Rituximab and ibrutinib | 1 | Relapsed | NCT03136497 |
| Venetoclax | Obinutuzumab and lenalidomide | 1 | Relapsed | NCT02992522 |
| Venetoclax | Obinutuzumab | 2 | Relapsed | NCT02987400 |
| Venetoclax | Rituximab and bortezomib | 2 | Relapsed | NCT02987400 |
| Venetoclax | Rituximab and idasanutlin | 1/2 | Relapsed | NCT03135262 |
| Venetoclax | RICE | 1/2 | Relapsed | NCT03064867 |
| Selinexor | RICE | 1 | Relapsed | NCT02471911 |
| Selinexor | RGDP or RDHAOx | 1b | Relapsed | NCT02741388 |
| Selinexor | Ibrutinib | 1 | Relapsed | NCT02303392 |
| Selinexor | Venetoclax | 1 | Relapsed | NCT03955783 |
| Selinexor | R-CHOP | 1b | Frontline | NCT031478850 |
| Agent . | Combination . | Phase . | Line of therapy . | Identifier . |
|---|---|---|---|---|
| Polatuzumab | Rituximab and lenalidomide | 1 | Relapsed | NCT02600897 |
| Polatuzumab | Obinutuzumab, rituximab, venetoclax | 1 | Relapsed | NCT02611323 |
| Polatuzumab | R-EPOCH | 1 | Frontline | NCT04231877 |
| Polatuzumab | ± RGemOx | 3 | Relapsed | NCT04182204 |
| Polatuzumab | + R-CHOP vs + R-CHP | 3 | Frontline | NCT04332822 |
| Venetoclax | Obinutuzumab, lenalidomide, ibrutinib, prednisone | 1 | Relapsed | NCT03223610 |
| Venetoclax | Rituximab and ibrutinib | 1 | Relapsed | NCT03136497 |
| Venetoclax | Obinutuzumab and lenalidomide | 1 | Relapsed | NCT02992522 |
| Venetoclax | Obinutuzumab | 2 | Relapsed | NCT02987400 |
| Venetoclax | Rituximab and bortezomib | 2 | Relapsed | NCT02987400 |
| Venetoclax | Rituximab and idasanutlin | 1/2 | Relapsed | NCT03135262 |
| Venetoclax | RICE | 1/2 | Relapsed | NCT03064867 |
| Selinexor | RICE | 1 | Relapsed | NCT02471911 |
| Selinexor | RGDP or RDHAOx | 1b | Relapsed | NCT02741388 |
| Selinexor | Ibrutinib | 1 | Relapsed | NCT02303392 |
| Selinexor | Venetoclax | 1 | Relapsed | NCT03955783 |
| Selinexor | R-CHOP | 1b | Frontline | NCT031478850 |
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; RDHAOx, rituximab dexamethasone, cytarabine, and oxaliplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; RGDP, rituximab, gemcitabine, dexamethasone, and cisplatin; RGemOx, rituximab, gemcitabine, and oxaliplatin; RICE, rituximab, ifosfamide, etoposide, and carboplatin.